These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30309289)

  • 1. How Much Time Before Attempting Compulsory Licensing of Pharmaceuticals? A Non-parametric Event History Model With P-splines.
    Son KB
    Int J Health Serv; 2019 Jan; 49(1):68-84. PubMed ID: 30309289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines.
    Son KB; Lee TJ
    Glob Public Health; 2018 Oct; 13(10):1430-1440. PubMed ID: 29183271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis.
    Son KB
    Global Health; 2019 Jun; 15(1):42. PubMed ID: 31248441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries.
    Guennif S
    Appl Health Econ Health Policy; 2017 Oct; 15(5):557-565. PubMed ID: 28120166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compulsory licensing of patents in India.
    Chaudhry R
    Pharm Pat Anal; 2016 Sep; 5(6):401-406. PubMed ID: 27805847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
    Guennif S
    Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding of for whom, under what conditions and how the compulsory licensing of pharmaceuticals works in Brazil and Thailand: A realist synthesis.
    Son KB; Kim CY; Lee TJ
    Glob Public Health; 2019 Jan; 14(1):122-134. PubMed ID: 29734843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.
    Qunaj L; Kaltenboeck A; Bach PB
    Milbank Q; 2022 Mar; 100(1):284-313. PubMed ID: 35257415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis.
    Beall R; Kuhn R
    PLoS Med; 2012 Jan; 9(1):e1001154. PubMed ID: 22253577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
    Xu Z; Chen W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
    Beall RF; Kuhn R; Attaran A
    Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

  • 15. The Legislative Approach and System Improvement of China's Compulsory Licensing for Drug Patents.
    Cao Z; Chen Y; Jiang W; Li W
    Drug Des Devel Ther; 2021; 15():3717-3731. PubMed ID: 34511881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDS, essential medicines, and compulsory licensing.
    Berman D
    J Int Assoc Physicians AIDS Care; 1999 Apr; 5(4):24-5. PubMed ID: 11367046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Affordability versus innovation: Is compulsory licensing the solution?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(4):233-247. PubMed ID: 31658067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.